




Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D., *et al.*
Serial No.: 10/565,699
Filed: January 25, 2006
Title: USE OF ROTIGOTINE FOR THE TREATMENT OF DEPRESSION
Group Art Unit: 1617
Examiner: K.D. Carter
Confirmation No.: 2513
Docket No.: 6102-000009/US/NP
Client Ref.: P/Sche/1/4/03

CERTIFICATE OF MAILING

I certify that this paper, together with any attachments thereto, is being deposited with the United States Postal Service with sufficient postage as FIRST CLASS MAIL in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 25, 2008.



Susan B. Gawlik

January 25, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant hereby submits an Information Disclosure Statement (IDS) under 37 C.F.R. §1.97(b) before the mailing of a first Office Action on the merits. No fee is believed payable in respect of this IDS. However, if any fee should be found payable, please charge such fee to Deposit Account No. 08-0750.

In accordance with 37 C.F.R. §1.97(g) and (h), this submission shall not be construed as representation that a search has been made or as admission that information presented or cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

In accordance with 37 C.F.R. §1.98, applicant submits herewith (1) a listing on Form PTO-1449 of documents requested to be considered by the Examiner; and (2) a legible copy of

each listed document, except for U.S. patents and U.S. patent application publications.

Applicant also submits herewith for the Examiner's convenience a copy of an International Search Report (ISR) and International Preliminary Report on Patentability dated May 29, 2006 in International Patent Application No. PCT/EP2004/008168, which represents the international phase of the present application.

In compliance with 37 C.F.R. §1.98(a)(3), Applicant provides the following statements of relevance, as presently understood by the individual designated in 37 C.F.R. §1.56(c) most knowledgeable of the contents, of those documents listed on attached Form PTO-1449 (a) which are not in the English language and (b) full English language translations of which are not in Applicant's possession. Where a full or partial English language translation of a non-English language document is available to Applicant, a copy of such translation is included in the present submission. No representation is made as to the accuracy of the translation or, in the case of partial translations, that all pertinent parts of a document have been translated.

DE 43 25 855. This publication appears to relate to benzoic acid derivatives having a generic formula as shown therein, and to a method for their preparation and application as drugs, for example for diseases of the central nervous system such as psychoses, depression, anxiety and schizophrenia, and as a sedative. The subject compounds are said to show a postsynaptic dopamine-antagonist effect but a presynaptic dopamine-agonist effect. An English language translation of the title, abstract and a part of the specification (page 3, line 52 – page 4, line 2) is appended to copy of DE 43 25 855 submitted herewith.

WO 2006/050976. This publication relates to a transdermal therapeutic system having a rotigotine-containing adhesive layer. Applicant is in possession of an English language translation, which is appended to the copy of WO 2006/050976.

The following publications are submitted as English language counterparts of foreign language publications. To the best of Applicant's belief, the English language publications listed below contain substantively similar disclosure to their foreign language counterparts.

CA 2546797 - counter part of WO 05/63238

CA 2568850 - counterpart of WO 06/15737

US 6,884,434 - counterpart of WO 99/49852

US 2003/166709 - counterpart of WO 02/15903

Serial No. 10/565,713
6102-000009/US/NP
Information Disclosure Statement
January 25, 2008


US 2004/072986 - counterpart of WO 02/38646

US 2005/175678 - counterpart of WO 04/58247

All documents cited are already of record in the present application or are now made of record by the present IDS.

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C.

A handwritten signature in black ink, appearing to read "James C. Forbes". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

James C. Forbes
Agent for Applicant
Reg. No. 39,457
Tel. 847-412-6350

Address Correspondence to:
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, MO 63105

Attachments

Form PTO-1449 (9 pgs)
ISR and International Preliminary Report on Patentability in PCT/EP2004/008168
Foreign Documents (36)
Other Documents (26)
Return Post Card